Inhalation drug delivery devices: technology update

References

• AndersonPJHistory of aerosol therapy: liquid nebulization to MDIs to DPIsRespir Care20055091139115016122398
   PubMedGoogle Scholar
• SandersMInhalation therapy: an historical reviewPrim Care Respir J2007162718117356785
   PubMedGoogle Scholar
• LabirisNRDolovichMBPulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medicationsBr J Clin Pharmacol200356658859914616418
   PubMed Web of Science ®Google Scholar
• CromptonGA brief history of inhaled asthma therapy over the last fifty yearsPrim Care Respir J200615632633117092772
   PubMedGoogle Scholar
• HessDRAerosol delivery devices in the treatment of asthmaRespir Care2008536699723 ; discussion 723–725.18501026
   PubMed Web of Science ®Google Scholar
• ChowAHTongHHChattopadhyayPShekunovBYParticle engineering for pulmonary drug deliveryPharm Res200724341143717245651
   PubMed Web of Science ®Google Scholar
• IbrahimMGarcia-ContrerasLMechanisms of absorption and elimination of drugs administered by inhalationTher Deliv2013481027104523919477
   PubMedGoogle Scholar
• VermaRKIbrahimMLucilaGCLung anatomy and physiology and their implications for pulmonary drug deliveryNokhodchiAPulmonary Drug Delivery: Advances and ChallengesOxford, UKJohn Wiley Publishers2014 inpress
   Google Scholar
• HeyderJParticle transport onto human airway surfacesEur J Respir Dis Suppl198211929506954086
   PubMedGoogle Scholar
• HindsWCLiuWCFroinesJRParticle bounce in a personal cascade impactor: a field evaluationAm Ind Hyg Assoc J19854695175234050689
   PubMed Web of Science ®Google Scholar
• ZanenPGoLTLammersJWThe efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhalerEur J Clin Pharmacol199854127309591926
   PubMed Web of Science ®Google Scholar
• FarrSJRoweAMRubsamenRTaylorGAerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhalerThorax19955066396447638806
   PubMed Web of Science ®Google Scholar
• AriARestrepoRDAmerican Association for Respiratory C. Aerosol delivery device selection for spontaneously breathing patients: 2012Respir Care201257461362622472501
   PubMed Web of Science ®Google Scholar
• NewmanSPAerosol deposition considerations in inhalation therapyChest198588Suppl 2152S160S3893925
   PubMed Web of Science ®Google Scholar
• LaubeBLJanssensHMde JonghFHWhat the pulmonary specialist should know about the new inhalation therapiesEur Respir J20113761308133121310878
   PubMed Web of Science ®Google Scholar
• ZhouQTTangPLeungSSChanJGChanHKEmerging inhalation aerosol devices and strategies: where are we headed?Adv Drug Deliv Rev201475C31724732364
   PubMed Web of Science ®Google Scholar
• DarquenneCAerosol deposition in health and diseaseJ Aerosol Med Pulm Drug Deliv201225314014722686623
   PubMed Web of Science ®Google Scholar
• DunbarCAHickeyAJHolznerPDispersion and characterization of pharmaceutical dry powder aerosolsKONA Powder Part J199816745
   Google Scholar
• HessDRNebulizers: principles and performanceRespir Care200045660962210894454
   PubMedGoogle Scholar
• WattsABMcConvilleJTWilliamsRO3rdCurrent therapies and technological advances in aqueous aerosol drug deliveryDrug Dev Ind Pharm200834991392218663654
   PubMed Web of Science ®Google Scholar
• RubinBKWilliamsRWEmerging aerosol drug delivery strategies: from bench to clinicAdv Drug Deliv Rev201475C14114824993613
   PubMed Web of Science ®Google Scholar
• DolovichMBDhandRAerosol drug delivery: developments in device design and clinical useLancet201137797701032104521036392
   PubMed Web of Science ®Google Scholar
• DaviesLANunez-AlonsoGAMcLachlanGHydeSCGillDRAerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapyHum Gene Ther Clin Dev20142529710724865497
   PubMed Web of Science ®Google Scholar
• PitanceLReychlerGLealTAerosol delivery to the lung is more efficient using an extension with a standard jet nebulizer than an open-vent jet nebulizerJ Aerosol Med Pulm Drug Deliv201326420821423286829
   PubMed Web of Science ®Google Scholar
• SkariaSSmaldoneGCOmron NE U22: comparison between vibrating mesh and jet nebulizerJ Aerosol Med Pulm Drug Deliv201023317318020500093
   PubMed Web of Science ®Google Scholar
• FischerAStegemannJScheuchGSiekmeierRNovel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trialsEur J Med Res200914Suppl 4717720156730
   PubMed Web of Science ®Google Scholar
• NikanderKPrinceICoughlinSWarrenSTaylorGMode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPAJ Aerosol Med Pulm Drug Deliv201023Suppl 1S37S4320373908
   PubMed Web of Science ®Google Scholar
• SabatoKWardPHawkWGildengorinVAsselinJMRandomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency departmentRespir Care201156676177021333060
   PubMed Web of Science ®Google Scholar
• LuisettiMKronebergPSuzukiTPhysical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizerPulm Pharmacol Ther201124112312720728558
   PubMed Web of Science ®Google Scholar
• CompAIR NE-C801. OMRON Healthcare Europe BV8192014 Available from: http://www.omron-healthcare.com/eu/en/our-products/respiratory-therapy/compair-ne-c801
   Google Scholar
• GellerDEKesserKCThe I-neb adaptive aerosol delivery system enhances delivery of alpha1-antitrypsin with controlled inhalationJ Aerosol Med Pulm Drug Deliv201023Suppl 1S55S5920373910
   PubMed Web of Science ®Google Scholar
• NajlahMParveenIAlhnanMAThe effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisersInt J Pharm20144611–223424124275450
   PubMed Web of Science ®Google Scholar
• GovoniMPoliGAcerbiDPharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patientsPulm Pharmacol Ther201326224925523232039
   PubMed Web of Science ®Google Scholar
• HodsonMEGallagherCGGovanJRA randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosisEur Respir J200220365866412358344
   PubMed Web of Science ®Google Scholar
• VaswaniSKCreticosPSMetered dose inhaler: past, present, and futureAnn Allergy Asthma Immunol19988011119 ; quiz 19–20.9475561
   PubMed Web of Science ®Google Scholar
• SmythHDThe influence of formulation variables on the performance of alternative propellant-driven metered dose inhalersAdv Drug Deliv Rev200355780782812842602
   PubMed Web of Science ®Google Scholar
• CummingsRHPressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performanceJ Allergy Clin Immunol19991046S230S23610588980
   PubMed Web of Science ®Google Scholar
• SteinSWShethPHodsonPDMyrdalPBAdvances in metered dose inhaler technology: hardware developmentAAPS PharmSciTech201415232633824357110
   PubMed Web of Science ®Google Scholar
• SmythHDPropellant-driven metered-dose inhalers for pulmonary drug deliveryExpert Opin Drug Deliv200521537416296735
   PubMedGoogle Scholar
• NewmanSPPrinciples of metered-dose inhaler designRespir Care20055091177119016122401
   PubMedGoogle Scholar
• LiHYSevillePCNovel pMDI formulations for pulmonary delivery of proteinsInt J Pharm20103851–2737819854252
   PubMed Web of Science ®Google Scholar
• BainsBKBirchallJCToonRTaylorGIn vitro reporter gene transfection via plasmid DNA delivered by metered dose inhalerJ Pharm Sci20109973089309920166201
   PubMed Web of Science ®Google Scholar
• HoeSBoraeyMAIveyJWFinlayWHVehringRManufacturing and device options for the delivery of biotherapeuticsJ Aerosol Med Pulm Drug Deliv201427531532824299502
   PubMed Web of Science ®Google Scholar
• LiYNLLiuMWebbKAddressing China’s growing need for inhaled drugs: development strategies for marketing, distribution, and regulationDalbyRNByronPRPeartJSumanJDFarrSYoungPMRespiratory Drug DeliveryRiver Grove, ILDavis Healthcare International Publishing, LLC2014131142
   Google Scholar
• CromptonGKBreath-activated aerosolBr Med J1971257626526535580735
   PubMed Web of Science ®Google Scholar
• LenneyJInnesJACromptonGKInappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICIRespir Med200094549650010868714
   PubMed Web of Science ®Google Scholar
• KelkarMSDalbyRNEffervescent aerosols: a novel formulation technology for pressurized metered dose inhalersDalbyRNByronPRPeartJSumanJDFarrSYoungPMRespiratory Drug DeliveryRiver Grove, ILDavis Healthcare International Publishing, LCC2014669672
   Google Scholar
• SteckelHMullerBWMetered-dose inhaler add-on devices: an in vitro evaluation of the BronchoAir inhaler and several spacer devicesJ Aerosol Med199811313314210186959
   PubMedGoogle Scholar
• TerzanoCManninoFProbability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and AutohalerMonaldi Arch Chest Dis19965132362428766201
   PubMedGoogle Scholar
• WildhaberJHWatererGWHallGLSummersQAReducing electrostatic charge on spacer devices and bronchodilator responseBr J Clin Pharmacol200050327728010971314
   PubMed Web of Science ®Google Scholar
• KunkelGMagnussenHBergmannKRespimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patientsRespiration200067330631410867600
   PubMed Web of Science ®Google Scholar
• DalbyRNEicherJZierenbergBDevelopment of Respimat® Soft Mist Inhaler and its clinical utility in respiratory disordersMed Devices20114145155
   Google Scholar
• LavoriniFThe challenge of delivering therapeutic aerosols to asthma patientsISRN Allergy2013201310241823984095
   PubMedGoogle Scholar
• US Food and Drug AdministrationFDA Approves Combivent Respimat (Ipratropium Bromide and Albuterol Sulfate) Inhalation SprayWashington DCUS Department of Health and Human Services [updated October 7, 2011/October 2, 2014]
   Google Scholar
• SanchisJCorriganCLevyMLViejoJLGroupAInhaler devices – from theory to practiceRespir Med2013107449550223290591
   PubMed Web of Science ®Google Scholar
• LippmannMYeatesDBAlbertREDeposition, retention, and clearance of inhaled particlesBr J Ind Med19803743373627004477
   PubMedGoogle Scholar
• ChanJGDukeCCOngHXA novel inhalable form of rifapentineJ Pharm Sci201410351411142124585270
   PubMed Web of Science ®Google Scholar
• BegatPMortonDAShurJKippaxPStaniforthJNPriceRThe role of force control agents in high-dose dry powder inhaler formulationsJ Pharm Sci20099882770278319067395
   PubMed Web of Science ®Google Scholar
• IslamNclearyMJDeveloping an efficient and reliable dry powder inhaler for pulmonarydrug delivery-a review for multidisciplinary researchersMedical engineering and physics201234440942722277307
   PubMed Web of Science ®Google Scholar
• Timothy CrowderMDScience and technology of dry powder inhalersSmythHDCHickeyAJControlled Pulmonary Drug DeliveryNew YorkSpringer2011203222
   Google Scholar
• BellJHHartleyPSCoxJSDry powder aerosols. I. A new powder inhalation deviceJ Pharm Sci19716010155915645129375
   PubMed Web of Science ®Google Scholar
• AshurstIIMaltonAPrimeDSumbyBLatest advances in the development of dry powder inhalersPharm Sci Technolo Today20003724625610884680
   PubMedGoogle Scholar
• AtkinsPJDry powder inhalers: an overviewRespir Care2005501013041312 ; discussion 1312.16185366
   PubMedGoogle Scholar
• TiddensHAGellerDEChallonerPEffect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and olderJ Aerosol Med200619445646517196074
   PubMedGoogle Scholar
• DunbarCAConcessioNMHickeyAJEvaluation of atomizer performance in production of respirable spray-dried particlesPharm Dev Technol1998344334419834945
   PubMedGoogle Scholar
• LabirisNRDolovichMBPulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBr J Clin Pharmacol200356660061214616419
   PubMed Web of Science ®Google Scholar
• CrowderTHickeyAWardenJinventorDry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages. United States patent US 20040025877 A12122004
   Google Scholar
• SystemsMDDComparative Performance of the 3MTM Taper Dry Powder Inhaler Device2011 Available from: http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?locale=en_WW&lmd=1314027541000&assetId=1273684150144&assetType=MMM_Image&blobAttribute=ImageFileAccessed October 2, 2014
   Google Scholar
• SystemsMDDDeveloping an Efficient Dry Powder Inhaler 3M Conix™ DPI2011 Available from: http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1301085878000&locale=en_WW&assetType=MMM_Image&assetId=1273680315945&blobAttribute=ImageFileAccessed October 2, 2014
   Google Scholar
• ChrystynHNiederlaenderCThe Genuair(R) inhaler: a novel, multidose dry powder inhalerInt J Clin Pract201266330931722340451
   PubMed Web of Science ®Google Scholar
• KanniessFScuriMVezzoliSFranciscoCPetruzzelliSExtrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trialPulm Pharmacol Ther2014
   Web of Science ®Google Scholar
• GeenaMPragatiRVrindaMBhumikaAJaideepAGRevolizer®: the next generation novel single dose dry powder inhalerDalbyRNByronPRPeartJSumanJDFarrSYoungPMRespiratory Drug DeliveryRiver Grove, ILDavis Healthcare International Publishing, LCC2014401404
   Google Scholar
• SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• OPKOINSPIROMATIC™ Available from http://investor.opko.com/releasedetail.cfm?ReleaseID=8500775222014Accessed at November 18, 2014
   Google Scholar
• VecturaPositive Results for Once-Daily Ultibro^® Breezhaler^® Versus Combination Therapy (Tiotropium Plus Formoterol)2014 [updated May 21, 2014; cited October 2, 2014]. Available from: http://www.vectura.com/media/press-releases/2014/21-may-2014a.aspxAccess-date 10.02.2014
   Google Scholar
• ManKind CorporationPatient-Focused Dry Powder Inhalers Available from: http://www.mannkindcorp.com/Collateral/Documents/English-US/102LR-DeviceTechTeaser-01.19.11.pdfAccessed October 2, 20142011
   Google Scholar
• VecturaVectura Announces CE Mark for Aspirair^® Inhaler2007 Available from: http://www.vectura.com/media/press-releases/archive/2007/2007-01-24.aspxAccessed October 2, 2014
   Google Scholar
• CipollaDCGondaIFormulation technology to repurpose drugs for inhalation deliveryDrug Discov Today: Ther Strateg201183–4123130
   Google Scholar
• SimisKLeiMLuATNicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato systemDrug Dev Ind Pharm200834993694218800254
   PubMed Web of Science ®Google Scholar
• Teva PharmaceuticalsProduct Monograph Adasuve (Loxapine) Inhalation Powder [updated October 02, 2014]. Available from: http://adasuve.com/PDF/Adasuve_Formulary_kit_Monograph.pdf5212014
   Google Scholar